Literature DB >> 16985076

Targeting changes in cancer: assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues.

Ruili Huang1, Anders Wallqvist, David G Covell.   

Abstract

The purpose of this study is to examine gene expression changes occurring in cancer from a pathway perspective by analyzing the level of pathway coherence in tumor tissues in comparison with their normal counterparts. Instability in pathway regulation patterns can be considered either as a result of or as a contributing factor to genetic instability and possibly cancer. Our analysis has identified pathways that show a significant change in their coherence level in tumor tissues, some of which are tumor type specific, indicating novel targets for cancer type-specific therapies. Pathways are found to have a general tendency to lose their gene expression coherence in tumor tissues when compared with normal tissues, especially for signaling pathways. The selective growth advantage of cancer cells over normal cells seems to originate from their preserved control over vital pathways to ensure survival and altered signaling, allowing excessive proliferation. We have additionally investigated the tissue-related instability of pathways, providing valuable clues to the cellular processes underlying the tumorigenesis and/or growth of specific cancer types. Pathways that contain known cancer genes (i.e., "cancer pathways") show significantly greater instability and are more likely to become incoherent in tumor tissues. Finally, we have proposed strategies to target instability (i.e., pathways that are prone to changes) by identifying compound groups that show selective activity against pathways with a detectable coherence change in cancer. These results can serve as guidelines for selecting novel agents that have the potential to specifically target a particular pathway that has relevance in cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16985076     DOI: 10.1158/1535-7163.MCT-06-0239

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  7 in total

Review 1.  Computational algorithms for in silico profiling of activating mutations in cancer.

Authors:  E Joseph Jordan; Keshav Patil; Krishna Suresh; Jin H Park; Yael P Mosse; Mark A Lemmon; Ravi Radhakrishnan
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.261

2.  Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.

Authors:  David G Covell
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

3.  A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.

Authors:  Susan D Mertins; Dominic A Scudiero; Melinda G Hollingshead; Raymond D Divelbiss; Michael C Alley; Anne Monks; David G Covell; Karen M Hite; David S Salomon; John E Niederhuber
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

4.  Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors.

Authors:  Yun-feng Qi; Yan-xin Huang; Yan Dong; Li-hua Zheng; Yong-li Bao; Lu-guo Sun; Yin Wu; Chun-lei Yu; Hong-yu Jiang; Yu-xin Li
Journal:  Comput Math Methods Med       Date:  2014-10-13       Impact factor: 2.238

5.  Blood vessel tortuosity selects against evolution of aggressive tumor cells in confined tissue environments: A modeling approach.

Authors:  András Szabó; Roeland M H Merks
Journal:  PLoS Comput Biol       Date:  2017-07-17       Impact factor: 4.475

6.  Identifying differential correlation in gene/pathway combinations.

Authors:  Rosemary Braun; Leslie Cope; Giovanni Parmigiani
Journal:  BMC Bioinformatics       Date:  2008-11-18       Impact factor: 3.169

7.  From molecular interaction to acute promyelocytic leukemia: Calculating leukemogenesis and remission from endogenous molecular-cellular network.

Authors:  Ruoshi Yuan; Xiaomei Zhu; Jerald P Radich; Ping Ao
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.